Stockreport

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ...

Nuvation Bio Inc. Class A  (NUVB) 
PDF Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years TRUST-I is one of two registrational Phase 2 studi [Read more]